Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review
- Author(s)
- Kashyap, R; Raja, S; Adusumilli, A; Gopireddy, MMR; Loveday, BPT; Alipour, R; Kong, G;
- Journal Title
- Journal of Neuroendocrinology
- Publication Type
- Online publication before print
- Abstract
- Peptide receptor radionuclide therapy (PRRT) is an established therapy for metastatic neuroendocrine neoplasms (NEN). The role of PRRT as a neoadjuvant treatment prior to surgery or other local therapies is uncertain. This scoping review aimed to define the landscape of evidence available detailing the utility of PRRT in the neo-adjuvant setting, including the clinical contexts, efficacy, and levels of evidence. A comprehensive literature search of PUBMED, SCOPUS, and EMBASE through to December 2022 was performed to identify reports of PRRT use as neoadjuvant therapy prior to local therapies. Observational studies and clinical trials were included. A total of 369 records were identified by the initial search, and 17 were included in the final analysis, comprising 179 patients treated with neoadjuvant PRRT. Publications included case reports, retrospective cohort series and a phase 2 trial. Definitions of unresectable disease were variable. Radioisotopes used included (177)Lu (n = 142) and (90)Y (n = 36), used separately (n = 178) or in combination (n = 1). A combination of PRRT with chemotherapy was also explored (n = 2). Toxicity data was reported in 11/17 studies. Survival analysis was reported in 3/17 studies. Surgical resection following PRRT was reported for both the primary tumor (n = 71) and metastases (n = 12). Resection rates could not be calculated as not all publications reported whether resection was completed. Published literature exploring the use of PRRT in the neoadjuvant setting is mostly limited to case reports and retrospective cohort studies. From these limited data there is reported to be a role of PRRT in neoadjuvant setting in the literature. However, the low quality of evidence precludes any definite conclusion on the grade of disease, site of primary, isotope used or use of concomitant chemotherapy that can benefit from this application. Further prospective studies will require collaboration between multiple centers to gain sufficient high-quality evidence.
- Keywords
- 177Lu/90Y DOTATATE; Prrt; neoadjuvant therapy; neuroendocrine tumors; surgery
- Department(s)
- Surgical Oncology; Molecular Imaging
- Publisher's Version
- https://doi.org/10.1111/jne.13425
- Open Access at Publisher's Site
https://doi.org/10.1111/jne.13425- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-06 05:29:14
Last Modified: 2024-08-06 05:31:19